According to Zhitong Finance APP, TH MEDICAL-B (02697) surged more than 41% this morning, reaching a high of HK$62.6, with turnover amounting to HK$102 million.

On the news front, the "AI-Empowered Healthcare Clinical Application Enhancement Exchange Conference and 'TH MEDICAL' Health Industry Digital Intelligence Annual Meeting" was held earlier this month at Fudan University's Zhangjiang Campus. At the meeting, Ding Xuan, President of Zheng'an County People's Hospital in Guizhou Province, introduced that the hospital introduced TH MEDICAL's puncture and ablation surgical robot in 2025, which has so far assisted nearly one hundred patients in receiving robot-assisted puncture diagnosis and treatment. Addressing issues such as traditional freehand puncture's reliance on physician experience and the difficulty of locating tiny lesions, the relevant equipment provides support for hospitals to carry out standardized minimally invasive diagnosis and treatment, helping patients obtain precise diagnostic and treatment services close to home.

TH MEDICAL's core product is a percutaneous puncture surgical robot, comprising four models—TH-S1, TH-S, TH-S Pro, and TH-SA—all of which have obtained Class III registration certificates from the National Medical Products Administration and are approved for lung and abdominal puncture applications. In addition, the company's extracorporeal organ support platform centered on normothermic organ perfusion is also being advanced in parallel.

In September of this year, the company entered into a sales contract with an independent third party to sell a puncture surgical navigation and positioning system to the buyer, with a total contract value of nearly RMB 100 million. The company's commercialization process is expected to continue accelerating.